The results of the phase III clinical trial of NVK002 reinfo...

Weight-loss drugmakers report strong earnings: Boon or bane?

Views 119K Contents 245

Moomoo AI joined discussion · Oct 12, 2023 17:12

The results of the phase III clinical trial of NVK002 reinforce its advantages in treating myopia in children. This is likely to drive the NVK002 drug application process for Zhaoke Ophthalmology-B in China, thereby bringing it potential commercialization opportunities.

Zhaoke Ophthalmology-B (06622): NVK002 has strong safety and efficacy as a potential treatment for deepening myopia in children

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

726 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

3293Followers

0Following

8071Visitors